The Slonomics platform will provide a a full set of ratio-controlled mutants that will allow bioMérieux to chose an enzyme with enhanced characteristics.
Sloning BioTechnology will carry out a feasibility study together with bioMérieux to generate a large number of gene variants of a particular enzyme that will be used in diagnostic applications.
Sloning will use its Slonomics™ gene synthesis technology to provide a gene library with a full set of ratio-controlled mutants. The successful completion of the study will enable bioMérieux to identify an enzyme with significantly enhanced characteristics, according to the companies.
“We are very excited about this collaboration. It gives Sloning the opportunity to demonstrate the capabilities of our enabling technology in the field of protein engineering and synthetic biology and in this particular case with a significant commercial impact to our customer,” states Heinz Schwer, Sloning’s CEO.